Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Prospective, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Type 1 Diabetes Patients With Celiac Disease While Undergoing Periodic Gluten Exposure
This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening.
A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease
Single Center, Randomized, Double-Blind, Placebo Controlled, Gluten Challenge Trial in Patients with Well-Controlled Celiac Disease
Simvastatin Metabolism as a Test for Celiac Disease Activity
To study the correlation between simvastatin metabolism by the enterocyte and the histologic state of the intestine in treated celiac disease.
100 Clinical Results associated with Immunogenics LLC
0 Patents (Medical) associated with Immunogenics LLC
100 Deals associated with Immunogenics LLC
100 Translational Medicine associated with Immunogenics LLC